Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
OCULAR THERAPEUTIX, INC OCUL

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Oct 16, 2026 8-K 1 signal fired
Core
Management Exodus
Aug 3, 2026 10-Q 25 signals fired · top 15
Other
Net Loss Reported Cash Flow Statement Investing Activities Rsu Psu Vesting Schedule Disclosed Interest Income Year Over Year Comparison Financing Activities Cash Flow Disclosure Interim Data Positive Stock Option Grant Disclosed Personnel Cost Decrease Disclosure Equity Plan Share Reserve Disclosure Fda Aligned Institutional Investment
Core
Secondary Endpoint Mentioned Indication Expansion Clinical Trial Result Combination Therapy Mentioned
Aug 3, 2026 8-K 15 signals fired
Other
Net Loss Reported Kol Endorsement Interim Data Positive Patient Retention High Fda Aligned Shares Outstanding Disclosure Fast Track Granted Enrollment Ahead Of Schedule Safety Differentiated
Core
Clinical Trial Result Lead Asset Progress Indication Expansion Combination Therapy Mentioned Secondary Endpoint Mentioned Clinical Hold
Jun 12, 2026 8-K 1 signal fired
Other
Rsu Psu Vesting Schedule Disclosed
May 5, 2026 10-Q 31 signals fired · top 15
Other
Litigation Defense Assertion Codm Segment Reporting Disclosure Cash Flow Statement Investing Activities Net Loss Reported Advertising Cost Disclosure Financing Activities Cash Flow Disclosure Tenant Restoration Obligation Rsu Psu Vesting Schedule Disclosed Patient Retention High Ipo Or Capital Raising Completion Interest Income Year Over Year Comparison Stock Option Grant Disclosed
Core
Indication Expansion Clinical Trial Result Secondary Endpoint Mentioned
May 5, 2026 8-K 19 signals fired · top 15
Other
Net Loss Reported Earnings Call Replay Details First Patient Treated Interim Data Positive Fda Aligned Publication Positive Enrollment Ahead Of Schedule Liquidity Position Snapshot Disclosed Fast Track Designation Received Protocol Amended
Core
Clinical Trial Result Secondary Endpoint Mentioned Lead Asset Progress Clinical Hold Combination Therapy Mentioned